In this free webinar, learn how teams are overcoming the unique challenges of preclinical Alzheimer's disease clinical trials. The featured speakers will share guidance on strategic rater selection, qualification and tailored training programs. The speakers will also discuss methods for effective central monitoring via algorithmic, data-based review and risk-based expert review. Attendees will gain insight into considerations for decentralized testing options to reduce site and patient burden and optimize data quality.
TORONTO, June 12, 2025 /PRNewswire-PRWeb/ -- Accurate and reliable signal detection remains a critical challenge in Alzheimer's disease (AD) clinical trials, particularly when targeting the preclinical phase where research teams must leverage different scales and operational approaches compared to studies of symptomatic AD.
Participants in these studies will be cognitively unimpaired or display only very subtle, prodromal cognitive changes, requiring extremely sensitive assessment instruments capable of detecting small, incremental changes over time. Furthermore, slow progression of AD necessitates longer trial duration to observe meaningful change, which increases risk for participant attrition and of inter/intra rater variability.
These realities can lead to more "noise" in trial data, potentially obscuring meaningful clinical outcomes and hindering development of novel therapeutics if effective signal detection strategies are not implemented.
In this webinar, attendees will learn tactics and hear case examples of various strategies clinical trial teams are deploying to improve data signal clarity and enhance the reliability of their study outcomes in preclinical AD. The expert speakers will describe the processes and benefits of:
- Strategic rater selection, robust qualification criteria and tailored training programs
- Central monitoring using both algorithmic, data-based review, as well as risk-based expert review of rater performance to flag errors and provide timely feedback to raters
- Remote, decentralized assessment options for preclinical populations such as central review and central rating using small groups of expert clinicians to administer/score scales remotely, enabling those sites lacking specialized raters to participate, increasing participant diversity and reducing participant burden
- eCOA form optimization to prevent common rater errors and enhance user experience for raters with effective data capture tools
The expert speakers will share first-hand experiences with the nuances of administering clinical outcome assessments to this specific patient population and provide tactics to deploy strong endpoint data quality programs for preclinical AD trials.
Register for this webinar to gain insights into how teams are overcoming the unique challenges of preclinical Alzheimer's disease clinical trials.
Join experts from Cogstate, Dr. Kaycee Sink, MD, MAS, Chief Medical Officer; and Dr. Svenja Wacker, PhD, Neuropsychology Science Director, for the live webinar on Monday, June 30, 2025, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Strategies That Drive Effective Signal Detection in Preclinical Alzheimer's Disease Clinical Trials.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], www.xtalks.com
SOURCE Xtalks
Share this article